Added 20 hours ago Drug news

Complete response letter for trastuzumab biosimilar.- Pfizer

Pfizer Inc.announced that it received a Complete Response Letter (CRL) from the FDA in response to the Biologics License Application...

Added 17 days ago Drug news

FDA issues complete response for Herzuma (trastuzumab biosimilar)in treatment of gastric cancer.- Celltrion.

The FDA has issued a complete response letter to Celltrion for its application for Herzuma (trastuzumab biosimilar) for the treatment...

Added 1 month ago Drug news

CHMP recommends approval of ABP 980 for breast cancer and gastric cancer.- Amgen + Allergan.

Amgen and Allergan announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...

Added 4 years ago

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous group of tumors with their origin in neuroendocrine cells of the embryological gut. This guideline focuses on diagnosis and pathology/molecular biology...

Added 5 years ago

BSG guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments.

Added 6 years ago

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.

Background: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer.

Added 4 days ago

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Objective: The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting".

Added 4 days ago

Weekday of cancer surgery in relation to prognosis.

Background: Later weekday of surgery seems to affect the prognosis adversely in oesophageal cancer, whereas any such influence on other cancer sites is unknown. This study aimed to test whether weekday of surgery influenced...

Added 5 months ago

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study (ERASG1)

This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.

Added 5 months ago

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.

Added 4 months ago